【PLOS ONE】新型血液检测,这次不测癌症,测早产
2016/08/11
血液检测是目前受研究者们青睐的领域,其中癌症筛查是研究得比较多的方向。然而,在一项新研究中,研究人员开发了一种用于预测早产风险的新型血液检测技术,这也是该领域中的一项突破。


由英国妇产科教授David Olson组建的国际团队开发了一种新型血液检测技术,但这次筛查的不是癌症,而是预测孕妇的自发性流产风险,相关结果发表在《PLOS ONE》杂志上。

早产已被世界卫生组织归为妊娠和围产期的健康问题之一。全球每年有1500万早产儿诞生,其中100万婴儿因此夭折,即便在发达国家,早产仍然是导致儿童死亡的主要原因之一。早产儿在生活中的患病概率也会更高,其中包括肥胖、糖尿病、心血管疾病和炎症性疾病等,因而早产的早期预测和干预十分重要。

该研究团队由临床医生、科学家以及生物统计学家组成,受试对象为加拿大2008年招募的3300名孕妇志愿者,目的是探索孕妇全血基因表达与自发性早产风险的相关性。

血液采集时间点为孕期17-23周和27-33周,研究人员对血液样本进行了RNA提取以及微阵列分析,通过单基因分析确定了临床因素、全血基因表达与早发性流产的相关性,此外,还对13个基因进行了荧光定量PCR验证。

研究结果发现,临床因素、全血基因组表达与无症状孕妇的早发性流产风险相关。

Olson教授说,“新方法十分重要,因为它能预测哪些女性会有早发性流产的风险,这将有助于开发新的药物和干预措施,从而延缓早产,对新生儿的健康很有意义。”

本文的合作作者,卡尔加里大学卡名医学院的Suzanne Tough教授说,“在孕早期明确孕妇的早发性流产风险,有助于临床医生采用个性化的方式来预防早产。开发一种可靠的筛查技术,如血液检测,可以实现在孕早期进行干预。”

然而,Olson教授指出,仍需进一步研究才能将该技术应用至临床。随着试验的进一步推进,他希望该研究能在几年内全部完成。“开发新的诊断技术是必要的,该方法是预防早产领域的突破。”

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Maternal Whole Blood Gene Expression at 18 and 28 Weeks of Gestation Associated with Spontaneous Preterm Birth in Asymptomatic Women

    The heterogeneity of spontaneous preterm birth (SPTB) requires an interdisciplinary approach to determine potential predictive risk factors of early delivery. The aim of this study was to investigate maternal whole blood gene expression profiles associated with spontaneous preterm birth (SPTB, <37 weeks) in asymptomatic pregnant women. The study population was a matched subgroup of women (51 SPTBs, 114 term delivery controls) who participated in the All Our Babies community based cohort in Calgary (n = 1878). Maternal blood at 17–23 (sampling time point 1, T1) and 27–33 weeks of gestation (T2) were collected. Total RNA was extracted and microarray was performed on 326 samples (165 women). Univariate analyses determined significant clinical factors and differential gene expression associated with SPTB. Thirteen genes were validated using qRT-PCR. Three multivariate logistic models were constructed to identify gene expression at T1 (Model A), T2 (Model B), and gene expression fold change from T1 to T2 (Model C) associated with SPTB. All models were adjusted for clinical factors. Model C can predict SPTB with 65% sensitivity and 88% specificity in asymptomatic women after adjusting for history of abortion and anaemia (occurring before T2). Clinical data enhanced the sensitivity of the Models to predict SPTB. In conclusion, clinical factors and whole blood gene expression are associated with SPTB in asymptomatic women. An effective screening tool for SPTB during pregnancy would enable targeted preventive approaches and personalised antenatal care.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test